Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

All subjects will receive Paclitaxel weekly for 12 weeks

All subjects will receive Trastuzumab every 3 weeks

Arm A and Arm B subjects will receive Pertuzumab every 3 weeks

Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks